|
|||||
|
|
A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors |
|
| Authors: | Stephen Leong Rebecca A. Moss Daniel W. Bowles Joseph A. Ware Jing Zhou Jill M. Spoerke Mark R. Lackner Geetha Shankar Jennifer L. Schutzman Ruud van der Noll Emile E. Voest Jan H.M. Schellens |
| Affiliation: | 1. Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA;2. Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA;3. Genentech, Inc., South San Francisco, California, USA;4. Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands;5. Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands;6. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands;7. Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |
| Abstract: | |
| Keywords: | Phosphatidylinositol 3‐kinase Phosphatidylinositol 3‐kinase inhibitor Pictilisib Erlotinib Erlotinib hydrochloride Epidermal growth factor receptor Epidermal growth factor receptor inhibitor Receptor protein‐tyrosine kinases Phase I clinical trial |